Biotech News

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Adial Pharmaceuticals (ADIL)Adial Pharmaceuticals2023-09-28 07:00 ESTCompany update

Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th

Industry experts to discuss the need for non-abstinence-based therapies in Alcohol Use Disorder (AUD)

CHARLOTTESVILLE, Va., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-13 08:30 EST

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

ADILAdial Pharmaceuticals2025-05-08 08:30 EST

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

ADILAdial Pharmaceuticals2025-05-02 11:48 EST

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data

Close: 6.22 USD
Market cap: 5.06M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States